Brief: Dimerix And Amicus Therapeutics Announce Exclusive License Agreement For DMX-200 In United States
01/05/2025 24:15
May 1 (Reuters) - Dimerix Ltd DXB.AX: DIMERIX AND AMICUS THERAPEUTICS ANNOUNCE EXCLUSIVE LICENSE AGREEMENT FOR DMX-200 IN UNITED STATES DIMERIX TO RECEIVE US$30 MILLION UPFRONT PAYMENT DIMERIX TO RECEIVE UP TO US$560 MILLION FOR SUCCESS-BASED MILESTONE PAYMENTS Further company coverage: DXB.AX ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Amicus Therapeutics
See all newsNASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT CONTINUES TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 03:28 AM
NASDAQ TRADE HALT CONTINUES TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 03:28 AM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM
Amicus Q4 revenue beats estimates